Codexis Inc (CDXS)

$2.43 -0.01 (-0.41%)
Market Cap 219.35M
Revenue (ttm) 59.35M
Net Income (ttm) -65.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -109.99%
Debt to Equity Ratio 0.71
Volume 508,600
Avg Vol 1,039,786
Day's Range N/A - N/A
Shares Out 90.27M
Stochastic %K 30%
Beta 2.54
Analysts Strong Sell
Price Target $7.08

Company Profile

Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with A...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 421 8100
Address:
200 Penobscot Drive, Redwood City, United States
Tacto
Tacto Sep. 14 at 10:22 AM
$CDXS https://patentskart.com/ai-based-enzyme-design-blog/
0 · Reply
PepCF
PepCF Sep. 13 at 10:06 PM
$CDXS
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 12 at 11:36 PM
Enter: $CDXS OCT 17 2025 $2 CALLS Buy in Price: $0.23 - $0.40 Take Profit: $0.26 Stop Bleeding: $0.20 ROI Potential: 12% Exit Within: 76 Minutes https://moneygroup.us/alerts
0 · Reply
Tacto
Tacto Sep. 12 at 10:50 PM
$CDXS Cash flow was positive today - Inflow: 332.85 Outflow: 318.68 .
0 · Reply
Tacto
Tacto Sep. 12 at 10:48 PM
$CDXS In the lower part of the picture there's a Stochastic Buy Signal, followed by Stochastic Oversold Reversal
0 · Reply
Tacto
Tacto Sep. 12 at 9:53 AM
$CDXS August 29, 2025 "In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Stephen Dilly, Chairman, President and Chief Executive Officer at Codexis" https://podcasts.apple.com/us/podcast/doc-to-ceo-40-years-of-reinvention-in-biopharma/id1509290866?i=1000724029586
0 · Reply
Tacto
Tacto Sep. 12 at 9:19 AM
$CDXS Short Interest report for the end of August was just published. It dropped nearly 200k from 2 weeks prior. After peaking at the end of June, it has been steadily declining, and this latest report comes in with the lowest short interest in 6 months, at about 5.5% .
0 · Reply
Tacto
Tacto Sep. 12 at 5:43 AM
$CDXS Bullish P&F Double Top Breakout pattern appeared today .
2 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 12 at 12:12 AM
Enter: $CDXS OCT 17 2025 $2 CALLS Buy in Price: $0.23 - $0.50 Take Profit: $0.32 Stop Bleeding: $0.20 ROI Potential: 40% Exit Within: 30 Minutes https://moneygroup.us/alerts
0 · Reply
Tacto
Tacto Sep. 11 at 9:17 AM
$CDXS OI on CDXS Call or Put options doesn't amount to a hill of beans, for any expiration date and strike price. Put that nonsense to rest!
0 · Reply
Latest News on CDXS
Codexis to Participate in Cantor Global Healthcare Conference

Aug 28, 2025, 9:00 AM EDT - 17 days ago

Codexis to Participate in Cantor Global Healthcare Conference

Codexis, Inc. (CDXS) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 7:57 PM EDT - 4 weeks ago

Codexis, Inc. (CDXS) Q2 2025 Earnings Call Transcript

Codexis Reports Second Quarter 2025 Financial Results

Aug 13, 2025, 4:05 PM EDT - 4 weeks ago

Codexis Reports Second Quarter 2025 Financial Results

Codexis to Report Second Quarter 2025 Financial Results on August 13

Jul 30, 2025, 4:05 PM EDT - 6 weeks ago

Codexis to Report Second Quarter 2025 Financial Results on August 13

Codexis' Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA

May 22, 2025, 7:00 AM EDT - 4 months ago

Codexis' Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA

Codexis to Participate in Jefferies Global Healthcare Conference

May 21, 2025, 4:05 PM EDT - 4 months ago

Codexis to Participate in Jefferies Global Healthcare Conference

Codexis, Inc. (CDXS) Q1 2025 Earnings Call Transcript

May 14, 2025, 6:50 PM EDT - 4 months ago

Codexis, Inc. (CDXS) Q1 2025 Earnings Call Transcript

Codexis Reports First Quarter 2025 Financial Results

May 14, 2025, 4:05 PM EDT - 4 months ago

Codexis Reports First Quarter 2025 Financial Results

Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting

May 7, 2025, 7:00 AM EDT - 4 months ago

Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting

Codexis to Report First Quarter 2025 Financial Results on May 14

Apr 30, 2025, 4:05 PM EDT - 4 months ago

Codexis to Report First Quarter 2025 Financial Results on May 14

Codexis Announces Byron Dorgan to Retire from Board of Directors

Apr 9, 2025, 5:00 PM EDT - 5 months ago

Codexis Announces Byron Dorgan to Retire from Board of Directors

Codexis Announces New Employment Inducement Grants

Mar 7, 2025, 4:05 PM EST - 6 months ago

Codexis Announces New Employment Inducement Grants

Codexis, Inc. (CDXS) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 10:20 PM EST - 7 months ago

Codexis, Inc. (CDXS) Q4 2024 Earnings Call Transcript

Codexis to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 27th

Feb 13, 2025, 4:05 PM EST - 7 months ago

Codexis to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 27th

Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board

Feb 6, 2025, 4:05 PM EST - 7 months ago

Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board

Codexis Appoints Christos Richards to Board of Directors

Jan 16, 2025, 4:05 PM EST - 8 months ago

Codexis Appoints Christos Richards to Board of Directors

Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 4:05 PM EST - 10 months ago

Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference

Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics

Nov 14, 2024, 4:05 PM EST - 10 months ago

Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics

Codexis Announces Appointment of Raymond De Vré, PhD, to Board of Directors

Nov 12, 2024, 4:05 PM EST - 10 months ago

Codexis Announces Appointment of Raymond De Vré, PhD, to Board of Directors

Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics

Nov 11, 2024, 4:05 PM EST - 10 months ago

Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics

Codexis to Participate in Upcoming Healthcare Conferences

Nov 4, 2024, 4:05 PM EST - 11 months ago

Codexis to Participate in Upcoming Healthcare Conferences

Codexis, Inc. (CDXS) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 10:48 PM EDT - 11 months ago

Codexis, Inc. (CDXS) Q3 2024 Earnings Call Transcript

Codexis Announces Three siRNA Manufacturing Data Presentations at TIDES Europe Annual Meeting

Oct 24, 2024, 4:05 PM EDT - 11 months ago

Codexis Announces Three siRNA Manufacturing Data Presentations at TIDES Europe Annual Meeting

Codexis to Report Third Quarter 2024 Financial Results on October 31

Oct 10, 2024, 4:05 PM EDT - 1 year ago

Codexis to Report Third Quarter 2024 Financial Results on October 31

Codexis Increases Cash Reserves and Enhances Management Team to Fuel Growth of Company

Oct 2, 2024, 4:05 PM EDT - 1 year ago

Codexis Increases Cash Reserves and Enhances Management Team to Fuel Growth of Company

Codexis Licenses Genomics Life Science Enzyme Portfolio to Alphazyme LLC, part of Maravai LifeSciences

Oct 1, 2024, 7:05 AM EDT - 1 year ago

Codexis Licenses Genomics Life Science Enzyme Portfolio to Alphazyme LLC, part of Maravai LifeSciences

Codexis to Participate in Enzymatic Synthesis Presentations at RNA Leaders Annual Meeting

Aug 20, 2024, 4:05 PM EDT - 1 year ago

Codexis to Participate in Enzymatic Synthesis Presentations at RNA Leaders Annual Meeting

Codexis Publishes FY2023 Sustainability Disclosures

Aug 15, 2024, 4:05 PM EDT - 1 year ago

Codexis Publishes FY2023 Sustainability Disclosures

Codexis, Inc. (CDXS) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 11:01 PM EDT - 1 year ago

Codexis, Inc. (CDXS) Q2 2024 Earnings Call Transcript

Codexis to Report Second Quarter 2024 Financial Results on August 8

Jul 18, 2024, 4:05 PM EDT - 1 year ago

Codexis to Report Second Quarter 2024 Financial Results on August 8

Codexis Finalizes Purchase Agreement with Crosswalk Therapeutics for Gene Therapy Assets

Jul 1, 2024, 4:05 PM EDT - 1 year ago

Codexis Finalizes Purchase Agreement with Crosswalk Therapeutics for Gene Therapy Assets

Codexis to Participate in TD Cowen 2nd Annual Sustainability Week

May 20, 2024, 4:05 PM EDT - 1 year ago

Codexis to Participate in TD Cowen 2nd Annual Sustainability Week

Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting

May 14, 2024, 6:00 AM EDT - 1 year ago

Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting

Codexis, Inc. (CDXS) Q1 2024 Earnings Call Transcript

May 2, 2024, 8:24 PM EDT - 1 year ago

Codexis, Inc. (CDXS) Q1 2024 Earnings Call Transcript

Codexis to Report First Quarter 2024 Financial Results on May 2

Apr 18, 2024, 4:05 PM EDT - 1 year ago

Codexis to Report First Quarter 2024 Financial Results on May 2

Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board

Apr 11, 2024, 7:05 AM EDT - 1 year ago

Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board

Codexis, Inc. (CDXS) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 10:39 PM EST - 1 year ago

Codexis, Inc. (CDXS) Q4 2023 Earnings Call Transcript

Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Feb 28, 2024, 4:05 PM EST - 1 year ago

Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche

Feb 26, 2024, 4:05 PM EST - 1 year ago

Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche

Codexis to Participate in TD Cowen 44th Annual Health Care Conference

Feb 26, 2024, 8:05 AM EST - 1 year ago

Codexis to Participate in TD Cowen 44th Annual Health Care Conference

Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board

Feb 20, 2024, 8:05 AM EST - 1 year ago

Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board

Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28

Feb 14, 2024, 4:05 PM EST - 1 year ago

Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28

Codexis Secures $40 Million in Strategic Financing Deal with Innovatus Capital Partners to Further Strengthen Cash Position Ahead of Key Milestones

Feb 13, 2024, 4:05 PM EST - 1 year ago

Codexis Secures $40 Million in Strategic Financing Deal with Innovatus Capital Partners to Further Strengthen Cash Position Ahead of Key Milestones

seqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General Meeting

Feb 1, 2024, 4:05 PM EST - 1 year ago

seqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General Meeting

Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108

Dec 27, 2023, 8:30 AM EST - 1 year ago

Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108

Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA Polymerase

Dec 13, 2023, 4:06 PM EST - 1 year ago

Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA Polymerase

Codexis Announces Achievement of Gram-scale Synthesis with its ECO Synthesis™ Platform

Dec 13, 2023, 4:05 PM EST - 1 year ago

Codexis Announces Achievement of Gram-scale Synthesis with its ECO Synthesis™ Platform

Codexis KOL Event Highlights Significant Need for an Enzymatic Route of Synthesis in RNAi Therapeutics Manufacturing

Dec 11, 2023, 7:05 AM EST - 1 year ago

Codexis KOL Event Highlights Significant Need for an Enzymatic Route of Synthesis in RNAi Therapeutics Manufacturing

Codexis to Host Virtual KOL Event on its ECO Synthesis™ Platform and the Future of RNAi Therapeutics Manufacturing on December 8, 2023

Nov 28, 2023, 4:05 PM EST - 1 year ago

Codexis to Host Virtual KOL Event on its ECO Synthesis™ Platform and the Future of RNAi Therapeutics Manufacturing on December 8, 2023

Codexis to Participate in 35th Annual Piper Sandler Healthcare Conference

Nov 14, 2023, 4:05 PM EST - 1 year ago

Codexis to Participate in 35th Annual Piper Sandler Healthcare Conference

Tacto
Tacto Sep. 14 at 10:22 AM
$CDXS https://patentskart.com/ai-based-enzyme-design-blog/
0 · Reply
PepCF
PepCF Sep. 13 at 10:06 PM
$CDXS
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 12 at 11:36 PM
Enter: $CDXS OCT 17 2025 $2 CALLS Buy in Price: $0.23 - $0.40 Take Profit: $0.26 Stop Bleeding: $0.20 ROI Potential: 12% Exit Within: 76 Minutes https://moneygroup.us/alerts
0 · Reply
Tacto
Tacto Sep. 12 at 10:50 PM
$CDXS Cash flow was positive today - Inflow: 332.85 Outflow: 318.68 .
0 · Reply
Tacto
Tacto Sep. 12 at 10:48 PM
$CDXS In the lower part of the picture there's a Stochastic Buy Signal, followed by Stochastic Oversold Reversal
0 · Reply
Tacto
Tacto Sep. 12 at 9:53 AM
$CDXS August 29, 2025 "In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Stephen Dilly, Chairman, President and Chief Executive Officer at Codexis" https://podcasts.apple.com/us/podcast/doc-to-ceo-40-years-of-reinvention-in-biopharma/id1509290866?i=1000724029586
0 · Reply
Tacto
Tacto Sep. 12 at 9:19 AM
$CDXS Short Interest report for the end of August was just published. It dropped nearly 200k from 2 weeks prior. After peaking at the end of June, it has been steadily declining, and this latest report comes in with the lowest short interest in 6 months, at about 5.5% .
0 · Reply
Tacto
Tacto Sep. 12 at 5:43 AM
$CDXS Bullish P&F Double Top Breakout pattern appeared today .
2 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 12 at 12:12 AM
Enter: $CDXS OCT 17 2025 $2 CALLS Buy in Price: $0.23 - $0.50 Take Profit: $0.32 Stop Bleeding: $0.20 ROI Potential: 40% Exit Within: 30 Minutes https://moneygroup.us/alerts
0 · Reply
Tacto
Tacto Sep. 11 at 9:17 AM
$CDXS OI on CDXS Call or Put options doesn't amount to a hill of beans, for any expiration date and strike price. Put that nonsense to rest!
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 11 at 7:00 AM
Enter: $CDXS OCT 17 2025 $2 CALLS Buy in Price: $0.23 - $3.00 Take Profit: $0.32 Stop Bleeding: $0.20 ROI Potential: 40% Exit Within: 78 Minutes https://moneygroup.us/alerts
0 · Reply
TheHowlingMadness
TheHowlingMadness Sep. 11 at 12:27 AM
$CDXS
0 · Reply
xbizo
xbizo Sep. 11 at 12:17 AM
$CDXS $2.50 options are the center of this battle. Market makers want them to expire worthless. Nothing more than 2.50 until after 9/19
0 · Reply
Fingerlickengood
Fingerlickengood Sep. 10 at 1:35 PM
$CDXS From 2nd quarter earnings: "In addition, three presentations from contract development and manufacturing organizations (CDMOs) including Bachem, Nitto Avecia, and ST Pharm validated the transferability of Codexis’ ligation processes to their in-house facilities." If $BCHMF, Nitto Avecia and ST Pharm incorporate the ECO Synthesis to some level across their manufacturing facilities equally, this will easily be a multibillion dollar company in the next few years! https://biz.chosun.com/en/en-science/2025/09/05/J42GIMB6MRC7XMX2532RSPWQAI/?outputType=amp
0 · Reply
Tacto
Tacto Sep. 9 at 11:48 PM
$CDXS Cash flow more positive Inflow: 258.83 Outflow: 165.22 They've stalled it here in the $2.40's while they erradicate impatient retail types .
1 · Reply
Wealth_
Wealth_ Sep. 9 at 2:33 PM
$CDXS bruh.. this needs some announcement.
1 · Reply
Wealth_
Wealth_ Sep. 9 at 1:06 PM
$CDXS mkt cap 218 > 221 going up
0 · Reply
Tacto
Tacto Sep. 8 at 10:13 PM
$CDXS Money flow was positive today, for the first time in quite a while. Looks like it has finally turned the corner Inflow: 268.25 Outflow: 230.19
0 · Reply
Jiggitus23
Jiggitus23 Sep. 8 at 7:17 PM
$CDXS plummeting down would have been more exciting than today’s price action
0 · Reply
buymoremakemore
buymoremakemore Sep. 8 at 4:40 PM
$CDXS could we see $4 or $5 on GMP Partnership announcement?
0 · Reply
buymoremakemore
buymoremakemore Sep. 8 at 1:37 PM
$CDXS Just got 15k mores shares
1 · Reply
buymoremakemore
buymoremakemore Sep. 8 at 12:44 AM
$CDXS Cant wait to buy more tomorrow
1 · Reply